{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-086059","form_type":"8-K","ticker":null,"cik":"0001305253","company_name":"Eiger BioPharmaceuticals, Inc.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.782584+00:00","generated_at":"2026-06-04T02:45:34.848352+00:00","sec_items":["3.01","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Eiger BioPharmaceuticals files Chapter 11, receives Nasdaq delisting notice; shares to trade OTC","bullets":["Filed Chapter 11 petitions on April 1, 2024; Nasdaq issued delisting notice on April 2.","Company will not appeal; trading suspended on Nasdaq effective April 11, 2024.","Common stock expected to trade OTC under symbol EIGRQ starting April 11, 2024.","Director Jeffrey S. Glenn resigned April 1, 2024, citing no disagreement with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-086059","json":"https://secwatch.observer/filing/0001193125-24-086059.json","markdown":"https://secwatch.observer/filing/0001193125-24-086059.md","text":"https://secwatch.observer/filing/0001193125-24-086059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/0001193125-24-086059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/d819347d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:45:34.848352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4023b5a31c6d8f0a656d187e2eca21ccc5f83f0","claim":"Eiger BioPharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).","evidence_excerpt":"April 2, 2024, the Company received written notice (the “ Delisting Notice ”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. The Delisting Notice also advises the Company of its right to appeal Nasdaq’s determination pursuant to procedures set forth in Nasdaq Listing Rule 5800 Series. The Company does not intend to pursue an appeal.","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/0001193125-24-086059-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Rules","value":"5101, 5110(b), IM-5101-1"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"ef9f8a6d8b","claim":"Jeffrey S. Glenn resigned as Member of the Board of Directors at Eiger BioPharmaceuticals, Inc..","evidence_excerpt":"On April 1, 2024, Jeffrey S. Glenn notified the Company of his resignation as a member of the Company’s Board of Directors, to be effective April 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/0001193125-24-086059-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}